Skip to content

A Trial of Sertraline in Young Children With Autism Spectrum Disorder

A Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02385799
Acronym
Sert2
Enrollment
58
Registered
2015-03-11
Start date
2015-04-30
Completion date
2018-07-31
Last updated
2019-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

Autism Spectrum Disorder, Behavior, sertraline, treatment

Brief summary

This study is a control trial of sertraline (Zoloft) in children aged 2 to 5 years old inclusive with Autism Spectrum Disorder. The trial is six months long, and each participant will receive a series of tests at both the beginning and end of the study. The researchers hope to show improvements in language and social deficits.

Detailed description

This is a single center study and the UC Davis MIND Institute for Autism Spectrum Disorder (ASD) patients aged between 2 years and 5 years old inclusive funded by the Health Resources and Services Administration (HRSA). It is a double-blind control trial of sertraline (Zoloft), an anti-depressant typically used in the treatment of depression, obsessive-compulsive disorder, panic disorder, and other conditions. The researchers are investigating the use of this selective serotonin reuptake inhibitor (SSRI) in ASD because a retrospective study has shown significant improvements in language and social deficits. There is also emerging evidence regarding the stimulation of brain-derived neurotrophic factor (BDNF) and the stimulation of neurogenesis when an SSRI is given early on in the development of animal models of Down syndrome. The researchers hope to see improvements in language stimulation, social gaze and social reciprocity, spatial attention, and a decrease in autistic behaviors. The aim of this study is to carry out a double-blind placebo controlled trial of sertraline in children with ASD who are between the ages of 2 years and 5 years old inclusive. At baseline, the researchers will assess behavioral and cognitive development. Each participant will be involved in this trial for a period of six months. This will include three visits to the UC Davis MIND Institute and eight phone calls. The researchers will also assess the side effects of the sertraline treatment throughout the study.

Interventions

DRUGSertraline Liquid Placebo

Liquid placebo given in parallel to active medication

DRUGSertraline

Active medication

Sponsors

Health Resources and Services Administration (HRSA)
CollaboratorFED
Randi J. Hagerman, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
24 Months to 72 Months
Healthy volunteers
No

Inclusion criteria

* Documentation of Autism Spectrum Disorder with Diagnostic and Statistical Manual for Mental Disorders-Fifth edition, criteria as well as a standardized autism assessment such as the Autism Diagnostic Observation Schedule or the Autism Diagnostic Interview-Revised. * Subject between the ages of 24-72 months of age. * A reliable parent or caregiver who can report the side effects and communicate effectively with the research team. * Stable medications during the two months prior to enrollment. * Currently receiving interventions in the community or school for Autism Spectrum Disorder

Exclusion criteria

* Current or past Selective Serotonin Reuptake Inhibitor treatment. * Other serious co-morbid medical disorders affecting brain function and behavior, including uncontrolled seizures.

Design outcomes

Primary

MeasureTime frameDescription
Change in Mullen Scales of Early Learning - Expressive Language Raw ScoreFrom baseline visit to six-month visitThe Mullen Scales of Early Learning (MSEL) is a cognitive test to measure cognitive ability and language development. The test has five scales: gross motor, visual reception, fine motor, receptive language, and expressive language. Shown here are the baseline and 6-month follow-up raw scores from the expressive language scale. This scale's raw scores range from 0 to 50. The lower the score on this scale, the weaker the ability; the higher the score, the greater the ability. The MSEL was administered at the baseline visit and at the 6-month follow-up visit.
Change in Mullen Scales of Early Learning - Combined Age Equivalent ScoreFrom baseline visit to six-month visitThe Mullen Scales of Early Learning (MSEL) is a cognitive test to measure cognitive ability and language development. The test has five scales: gross motor, visual reception, fine motor, receptive language, and expressive language. Shown here are the baseline and 6-month follow-up combined age equivalent scores, calculated as the sum of the age equivalent scores from each scale. The combined score ranges from 0 to 280. The lower the score on this scale, the weaker the ability; the higher the score, the greater the ability. The MSEL was administered at the baseline visit and at the 6-month follow-up visit.

Secondary

MeasureTime frameDescription
Preschool Language Scale-Fifth Edition - Total Language Raw ScoreAt baseline visitThe Preschool Language Scale-Fifth Edition (PLS-5) is designed to measure auditory comprehension (AC) and expressive communication (EC) for children from birth to 7 years 11 months. The measure examines the child's attention, play, gestures, social communication, semantics, language structure, integrative language skills and emergent literacy skills. The PLS-5 has expanded coverage of early play behaviors, concepts, theory of mind, and emergent literacy skills. The PLS-5 yields norm-referenced scores including standard scores, percentile ranks and age equivalents for the AC and EC scales as well as for Total Language (TL). Raw score ranges are 0 to 65 in AC, 0 to 67 in EC, and therefore 0 to 132 in TL (calculated by summing AC+EC raw scores). The higher the scores, the greater the language ability. Shown here are the mean TL raw scores from the baseline visit.
Sensory Processing Measure-Preschool - Social Participation Raw ScoreAt baseline visitThe Sensory Processing Measure-Preschool (SPM-P) is a questionnaire measuring specific problems, including under- and over-responsiveness, sensory-seeking behavior, and perceptual problems in multiple environments (at home, at school, and in the community) for children aged 2 to 5 years old, as reported by the parent/caregiver. The SPM-P provides norm-referenced standard scores for two higher-level integrative functions (praxis and social participation) and five sensor sensory systems (visual, auditory, tactile, proprioceptive, and vestibular functioning). Reported here is the Social Participation subscale mean raw score at baseline, which ranges from 8 to 32. The lower the raw score, the more limited the child's level of social participation. The higher the score, the greater the child's level of social participation.
Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard ScoreAt baseline visitThe Vineland-II measures the personal and social skills of individuals from birth through adulthood. It was designed to assess handicapped and non-handicapped persons in their personal and social functioning and is appropriate for individuals of all ages. The Vineland-II is a survey that is administered to a parent or caregiver using a semi-structured interview format and is organized around four Behavior Domains: Communication, Daily Living Skills, Socialization, and Motor Skills. Each subtest is scored with a standard score X=100 ± 15 and summed to calculate the Adaptive Behavior Composite (ABC) using age-adjusted scoring tables. Reported here are the ABC mean standard scores for the placebo and treatment groups at baseline. The ABC ranges from 20 to 160 and indicates low (20-70), moderately low (70-85), adequate (85-115), moderately high (115-130), or high (130-160) overall adaptive functioning.
Clinical Global Impression Scale-Improvement (CGI-I)At three-month visitThe Clinical Global Impression-Improvement (CGI-I) is a 7-point scale completed by a clinician that yields a score measuring the overall behavioral change of an individual and their therapeutic response. The 7-point scale ranges from: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse. Therefore, the lower the score, the greater the behavioral improvement as rated by the clinician. The CGI-I was administered at the three-month and six-month visits. Shown here are the CGI-I mean scores from the 3-month follow-up visit.
Visual Analog Scale - Language/Communication ScoreAt baseline visitThe Visual Analog Scale measures the severity of three specific behavioral symptoms as reported by the parent/caregiver: Language/Communication, Anxiety/Obsessive Compulsive Behaviors, and Aggression/Hyperactivity/Hyperarousal. Caregivers mark on a visual line measuring 10 cm with worst behavior at 0 cm and best behavior at 10 cm. For each behavior the caregiver is instructed to mark their impression of the behavior at baseline visit and again at the six-month visit. The calculated distance in cm between the marks drawn at the baseline and six-month visits thereby demonstrates whether each behavior improved, worsened, or stayed the same during the study, and by how much. Shown here is the mean distance in cm from the worst behavior side for the Language/Communication scale, at baseline. The smaller the value, the worse the behavior. The range is minimum 0 cm to maximum 10 cm.
Clinical Global Impression Scale-Severity (CGI-S)At baseline visitThe Clinical Global Impression-Severity (CGI-S) is a 7-point scale completed by a clinician that yields a rating of the patient's illness severity at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. The 7-point scale ranges from: 1 = Normal; 2 = Borderline Ill; 3 = Mildly Ill; 4 = Moderately Ill; 5 = Markedly Ill; 6 = Severely Ill; and 7 = Extremely Ill. Therefore, the higher the score, the greater the severity of the patient's illness. The CGI-S was administered at baseline only for the purpose of characterizing the study population. Shown here are the CGI-S mean scores from the baseline visit.
Preschool Anxiety Scale-Revised - Total ScoreAt baseline visitPreschool Anxiety Scale-Revised (PAS-R) is a questionnaire designed to assess symptoms of anxiety and fears in young children aged 6 and below as reported by their parents. The PAS-R consists of 34 questions, each with a rating option of 0 to 4 where 0=not true at all, 1=seldom true, 2=sometimes true, 3=quite often true, and 4=very often true. The total score is calculated as the sum of all responses and therefore ranges from 0 to 136. Lower scores indicate less anxiety/fear; higher scores indicate more anxiety/fear. Reported here are the mean total scores for the placebo and treatment groups at baseline.

Countries

United States

Participant flow

Participants by arm

ArmCount
Sertraline Liquid Placebo
The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age at enrollment will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4-5 years at enrollment will be given 5 mg of liquid placebo once per day for a period of six months. Sertraline Liquid Placebo: Liquid placebo given in parallel to active medication
26
Sertraline Active Medication
Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age at enrollment will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4-5 years at enrollment will be given 5 mg of liquid sertraline once per day for a period of six months. Sertraline: Active medication
32
Total58

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event42
Overall StudyLost to Follow-up12
Overall StudyWithdrawal by Subject04

Baseline characteristics

CharacteristicSertraline Liquid PlaceboSertraline Active MedicationTotal
Age, Categorical
<=18 years
26 Participants32 Participants58 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous3.70 years
STANDARD_DEVIATION 1.1
4.31 years
STANDARD_DEVIATION 0.9
4.005 years
STANDARD_DEVIATION 1
Ethnicity (NIH/OMB)
Hispanic or Latino
8 Participants3 Participants11 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
18 Participants29 Participants47 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
4 Participants7 Participants11 Participants
Race (NIH/OMB)
Black or African American
2 Participants5 Participants7 Participants
Race (NIH/OMB)
More than one race
2 Participants1 Participants3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
18 Participants19 Participants37 Participants
Region of Enrollment
United States
26 participants32 participants58 participants
Sex: Female, Male
Female
5 Participants7 Participants12 Participants
Sex: Female, Male
Male
21 Participants25 Participants46 Participants
The Autism Diagnostic Observation Schedule-Second Edition (ADOS-2)7.88 units on a scale
STANDARD_DEVIATION 1.62
7.34 units on a scale
STANDARD_DEVIATION 1.58
7.58 units on a scale
STANDARD_DEVIATION 1.6

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 260 / 32
other
Total, other adverse events
26 / 2630 / 32
serious
Total, serious adverse events
0 / 261 / 32

Outcome results

Primary

Change in Mullen Scales of Early Learning - Combined Age Equivalent Score

The Mullen Scales of Early Learning (MSEL) is a cognitive test to measure cognitive ability and language development. The test has five scales: gross motor, visual reception, fine motor, receptive language, and expressive language. Shown here are the baseline and 6-month follow-up combined age equivalent scores, calculated as the sum of the age equivalent scores from each scale. The combined score ranges from 0 to 280. The lower the score on this scale, the weaker the ability; the higher the score, the greater the ability. The MSEL was administered at the baseline visit and at the 6-month follow-up visit.

Time frame: From baseline visit to six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned voluntarily to complete follow-up assessments, so 26 subjects were analyzed at follow-up.

ArmMeasureGroupValue (MEAN)Dispersion
Sertraline Liquid PlaceboChange in Mullen Scales of Early Learning - Combined Age Equivalent ScoreBaseline25.61 score on a scaleStandard Deviation 11.73
Sertraline Liquid PlaceboChange in Mullen Scales of Early Learning - Combined Age Equivalent ScoreFollow-up30.30 score on a scaleStandard Deviation 15.58
Sertraline Active MedicationChange in Mullen Scales of Early Learning - Combined Age Equivalent ScoreBaseline24.98 score on a scaleStandard Deviation 12.79
Sertraline Active MedicationChange in Mullen Scales of Early Learning - Combined Age Equivalent ScoreFollow-up28.16 score on a scaleStandard Deviation 14.15
Primary

Change in Mullen Scales of Early Learning - Expressive Language Raw Score

The Mullen Scales of Early Learning (MSEL) is a cognitive test to measure cognitive ability and language development. The test has five scales: gross motor, visual reception, fine motor, receptive language, and expressive language. Shown here are the baseline and 6-month follow-up raw scores from the expressive language scale. This scale's raw scores range from 0 to 50. The lower the score on this scale, the weaker the ability; the higher the score, the greater the ability. The MSEL was administered at the baseline visit and at the 6-month follow-up visit.

Time frame: From baseline visit to six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned voluntarily to complete follow-up assessments, so 26 subjects were analyzed at follow-up.

ArmMeasureGroupValue (MEAN)Dispersion
Sertraline Liquid PlaceboChange in Mullen Scales of Early Learning - Expressive Language Raw ScoreBaseline19.69 score on a scaleStandard Deviation 11.69
Sertraline Liquid PlaceboChange in Mullen Scales of Early Learning - Expressive Language Raw ScoreFollow-up21.81 score on a scaleStandard Deviation 14.29
Sertraline Active MedicationChange in Mullen Scales of Early Learning - Expressive Language Raw ScoreBaseline18.19 score on a scaleStandard Deviation 10.39
Sertraline Active MedicationChange in Mullen Scales of Early Learning - Expressive Language Raw ScoreFollow-up20.31 score on a scaleStandard Deviation 11.7
Secondary

Clinical Global Impression Scale-Improvement (CGI-I)

The Clinical Global Impression-Improvement (CGI-I) is a 7-point scale completed by a clinician that yields a score measuring the overall behavioral change of an individual and their therapeutic response. The 7-point scale ranges from: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse. Therefore, the lower the score, the greater the behavioral improvement as rated by the clinician. The CGI-I was administered at the three-month and six-month visits. Shown here are the CGI-I mean scores from the 3-month follow-up visit.

Time frame: At three-month visit

Population: Placebo group: 3 discontinued treatment/become lost to follow-up prior to reaching 3-month visit, so 23 subjects were analyzed at this timepoint. Sertraline group: 5 discontinued treatment/become lost to follow-up prior to reaching 3-month visit, so 27 subjects were analyzed at this timepoint.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboClinical Global Impression Scale-Improvement (CGI-I)2.65 score on a scaleStandard Deviation 1.11
Sertraline Active MedicationClinical Global Impression Scale-Improvement (CGI-I)2.70 score on a scaleStandard Deviation 1.03
Secondary

Clinical Global Impression Scale-Improvement (CGI-I)

The Clinical Global Impression-Improvement (CGI-I) is a 7-point scale completed by a clinician that yields a score measuring the overall behavioral change of an individual and their therapeutic response. The 7-point scale ranges from: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse. Therefore, the lower the score, the greater the behavioral improvement as rated by the clinician. The CGI-I was administered at the three-month and six-month visits. Shown here are the CGI-I mean scores from the 6-month follow-up visit.

Time frame: At six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned voluntarily to complete follow-up assessments, so 26 subjects were analyzed at follow-up.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboClinical Global Impression Scale-Improvement (CGI-I)1.14 score on a scaleStandard Deviation 0.96
Sertraline Active MedicationClinical Global Impression Scale-Improvement (CGI-I)1.23 score on a scaleStandard Deviation 1.11
Secondary

Clinical Global Impression Scale-Severity (CGI-S)

The Clinical Global Impression-Severity (CGI-S) is a 7-point scale completed by a clinician that yields a rating of the patient's illness severity at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. The 7-point scale ranges from: 1 = Normal; 2 = Borderline Ill; 3 = Mildly Ill; 4 = Moderately Ill; 5 = Markedly Ill; 6 = Severely Ill; and 7 = Extremely Ill. Therefore, the higher the score, the greater the severity of the patient's illness. The CGI-S was administered at baseline only for the purpose of characterizing the study population. Shown here are the CGI-S mean scores from the baseline visit.

Time frame: At baseline visit

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboClinical Global Impression Scale-Severity (CGI-S)4.38 score on a scaleStandard Deviation 0.98
Sertraline Active MedicationClinical Global Impression Scale-Severity (CGI-S)4.66 score on a scaleStandard Deviation 0.94
Secondary

Preschool Anxiety Scale-Revised - Total Score

Preschool Anxiety Scale-Revised (PAS-R) is a questionnaire designed to assess symptoms of anxiety and fears in young children aged 6 and below as reported by their parents. The PAS-R consists of 34 questions, each with a rating option of 0 to 4 where 0=not true at all, 1=seldom true, 2=sometimes true, 3=quite often true, and 4=very often true. The total score is calculated as the sum of all responses and therefore ranges from 0 to 136. Lower scores indicate less anxiety/fear; higher scores indicate more anxiety/fear. Reported here are the mean total scores for the placebo and treatment groups at baseline.

Time frame: At baseline visit

Population: Placebo group: staff inadvertently neglected to administer this questionnaire to the 2 subjects' caregivers at baseline, so only 24 were completed.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboPreschool Anxiety Scale-Revised - Total Score15.38 score on a scaleStandard Deviation 12.51
Sertraline Active MedicationPreschool Anxiety Scale-Revised - Total Score14.75 score on a scaleStandard Deviation 11.58
Secondary

Preschool Anxiety Scale-Revised - Total Score

Preschool Anxiety Scale-Revised (PAS-R) is a questionnaire designed to assess symptoms of anxiety and fears in young children aged 6 and below as reported by their parents. The PAS-R consists of 34 questions, each with a rating option of 0 to 4 where 0=not true at all, 1=seldom true, 2=sometimes true, 3=quite often true, and 4=very often true. The total score is calculated as the sum of all responses and therefore ranges from 0 to 136. Lower scores indicate less anxiety/fear; higher scores indicate more anxiety/fear. Reported here are the mean total scores for the placebo and treatment groups at the six-month visit.

Time frame: At six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned voluntarily to complete follow-up assessments, so 26 subjects were analyzed at follow-up.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboPreschool Anxiety Scale-Revised - Total Score11.43 score on a scaleStandard Deviation 10.04
Sertraline Active MedicationPreschool Anxiety Scale-Revised - Total Score14.77 score on a scaleStandard Deviation 14.45
Secondary

Preschool Language Scale-Fifth Edition - Total Language Raw Score

The Preschool Language Scale-Fifth Edition (PLS-5) is designed to measure auditory comprehension (AC) and expressive communication (EC) for children from birth to 7 years 11 months. The measure examines the child's attention, play, gestures, social communication, semantics, language structure, integrative language skills and emergent literacy skills. The PLS-5 has expanded coverage of early play behaviors, concepts, theory of mind, and emergent literacy skills. The PLS-5 yields norm-referenced scores including standard scores, percentile ranks and age equivalents for the AC and EC scales as well as for Total Language (TL). Raw score ranges are 0 to 65 in AC, 0 to 67 in EC, and therefore 0 to 132 in TL (calculated by summing AC+EC raw scores). The higher the scores, the greater the language ability. Shown here are the mean TL raw scores from the six-month visit.

Time frame: At six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned for an end-of-treatment visit, but due to time limitations only 1 of these 2 completed this assessment, so 25 subjects were analyzed at follow-up.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboPreschool Language Scale-Fifth Edition - Total Language Raw Score57.24 score on a scaleStandard Deviation 26.26
Sertraline Active MedicationPreschool Language Scale-Fifth Edition - Total Language Raw Score51.40 score on a scaleStandard Deviation 23.56
Secondary

Preschool Language Scale-Fifth Edition - Total Language Raw Score

The Preschool Language Scale-Fifth Edition (PLS-5) is designed to measure auditory comprehension (AC) and expressive communication (EC) for children from birth to 7 years 11 months. The measure examines the child's attention, play, gestures, social communication, semantics, language structure, integrative language skills and emergent literacy skills. The PLS-5 has expanded coverage of early play behaviors, concepts, theory of mind, and emergent literacy skills. The PLS-5 yields norm-referenced scores including standard scores, percentile ranks and age equivalents for the AC and EC scales as well as for Total Language (TL). Raw score ranges are 0 to 65 in AC, 0 to 67 in EC, and therefore 0 to 132 in TL (calculated by summing AC+EC raw scores). The higher the scores, the greater the language ability. Shown here are the mean TL raw scores from the baseline visit.

Time frame: At baseline visit

Population: Sertraline group: 2 subjects were completely nonverbal at baseline, so the rater determined that their assessments could not be completed; therefore, only 30 subjects in this arm were analyzed at baseline.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboPreschool Language Scale-Fifth Edition - Total Language Raw Score48.65 score on a scaleStandard Deviation 25.57
Sertraline Active MedicationPreschool Language Scale-Fifth Edition - Total Language Raw Score43.03 score on a scaleStandard Deviation 23.35
Secondary

Sensory Processing Measure-Preschool - Social Participation Raw Score

The Sensory Processing Measure-Preschool (SPM-P) is a questionnaire measuring specific problems, including under- and over-responsiveness, sensory-seeking behavior, and perceptual problems in multiple environments (at home, at school, and in the community) for children aged 2 to 5 years old, as reported by the parent/caregiver. The SPM-P provides norm-referenced standard scores for two higher-level integrative functions (praxis and social participation) and five sensor sensory systems (visual, auditory, tactile, proprioceptive, and vestibular functioning). Reported here is the Social Participation subscale mean raw score at the six-month visit, which ranges from 8 to 32. The lower the raw score, the more limited the child's level of social participation. The higher the score, the greater the child's level of social participation.

Time frame: At six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned for an end-of-treatment visit, but due to time limitations only 1 of these 2 completed this assessment, so 25 subjects were analyzed at follow-up.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboSensory Processing Measure-Preschool - Social Participation Raw Score20.86 score on a scaleStandard Deviation 4.07
Sertraline Active MedicationSensory Processing Measure-Preschool - Social Participation Raw Score21.16 score on a scaleStandard Deviation 5.04
Secondary

Sensory Processing Measure-Preschool - Social Participation Raw Score

The Sensory Processing Measure-Preschool (SPM-P) is a questionnaire measuring specific problems, including under- and over-responsiveness, sensory-seeking behavior, and perceptual problems in multiple environments (at home, at school, and in the community) for children aged 2 to 5 years old, as reported by the parent/caregiver. The SPM-P provides norm-referenced standard scores for two higher-level integrative functions (praxis and social participation) and five sensor sensory systems (visual, auditory, tactile, proprioceptive, and vestibular functioning). Reported here is the Social Participation subscale mean raw score at baseline, which ranges from 8 to 32. The lower the raw score, the more limited the child's level of social participation. The higher the score, the greater the child's level of social participation.

Time frame: At baseline visit

Population: Placebo group: staff inadvertently neglected to administer this questionnaire to 1 subject's caregiver at baseline, so only 25 were completed. Sertraline group: staff inadvertently neglected to administer this questionnaire to 1 subject's caregiver at baseline, so only 31 were completed.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboSensory Processing Measure-Preschool - Social Participation Raw Score21.96 score on a scaleStandard Deviation 3.81
Sertraline Active MedicationSensory Processing Measure-Preschool - Social Participation Raw Score22.39 score on a scaleStandard Deviation 5.1
Secondary

Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score

The Vineland-II measures the personal and social skills of individuals from birth through adulthood. It was designed to assess handicapped and non-handicapped persons in their personal and social functioning and is appropriate for individuals of all ages. The Vineland-II is a survey that is administered to a parent or caregiver using a semi-structured interview format and is organized around four Behavior Domains: Communication, Daily Living Skills, Socialization, and Motor Skills. Each subtest is scored with a standard score X=100 ± 15 and summed to calculate the Adaptive Behavior Composite (ABC) using age-adjusted scoring tables. Reported here are the ABC mean standard scores for the placebo and treatment groups at the six-month visit. The ABC ranges from 20 to 160 and indicates low (20-70), moderately low (70-85), adequate (85-115), moderately high (115-130), or high (130-160) overall adaptive functioning.

Time frame: At six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned for an end-of-treatment visit, but due to time limitations only 1 of these 2 completed this assessment, so 25 subjects were analyzed at follow-up.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboVineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score71.52 score on a scaleStandard Deviation 15.47
Sertraline Active MedicationVineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score69.68 score on a scaleStandard Deviation 15.14
Secondary

Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score

The Vineland-II measures the personal and social skills of individuals from birth through adulthood. It was designed to assess handicapped and non-handicapped persons in their personal and social functioning and is appropriate for individuals of all ages. The Vineland-II is a survey that is administered to a parent or caregiver using a semi-structured interview format and is organized around four Behavior Domains: Communication, Daily Living Skills, Socialization, and Motor Skills. Each subtest is scored with a standard score X=100 ± 15 and summed to calculate the Adaptive Behavior Composite (ABC) using age-adjusted scoring tables. Reported here are the ABC mean standard scores for the placebo and treatment groups at baseline. The ABC ranges from 20 to 160 and indicates low (20-70), moderately low (70-85), adequate (85-115), moderately high (115-130), or high (130-160) overall adaptive functioning.

Time frame: At baseline visit

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboVineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score68.50 score on a scaleStandard Deviation 11.14
Sertraline Active MedicationVineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score60.03 score on a scaleStandard Deviation 12.15
Secondary

Visual Analog Scale - Language/Communication Score

The Visual Analog Scale measures the severity of three specific behavioral symptoms as reported by the parent/caregiver: Language/Communication, Anxiety/Obsessive Compulsive Behaviors, and Aggression/Hyperactivity/Hyperarousal. Caregivers mark on a visual line measuring 10 cm with worst behavior at 0 cm and best behavior at 10 cm. For each behavior the caregiver is instructed to mark their impression of the behavior at baseline visit and again at the six-month visit. The calculated distance in cm between the marks drawn at the baseline and six-month visits thereby demonstrates whether each behavior improved, worsened, or stayed the same during the study, and by how much. Shown here is the mean distance in cm from the worst behavior side for the Language/Communication scale, at baseline. The smaller the value, the worse the behavior. The range is minimum 0 cm to maximum 10 cm.

Time frame: At baseline visit

Population: Placebo group: staff inadvertently neglected to administer this assessment to 1 subject's caregiver at baseline, so only 25 were completed. Sertraline group: staff inadvertently neglected to administer this assessment to 1 subject's caregiver at baseline, so only 31 were completed.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboVisual Analog Scale - Language/Communication Score2.84 centimetersStandard Deviation 2.04
Sertraline Active MedicationVisual Analog Scale - Language/Communication Score2.03 centimetersStandard Deviation 1.7
Secondary

Visual Analog Scale - Language/Communication Score

The Visual Analog Scale measures the severity of three specific behavioral symptoms as reported by the parent/caregiver: Language/Communication, Anxiety/Obsessive Compulsive Behaviors, and Aggression/Hyperactivity/Hyperarousal. Caregivers mark on a visual line measuring 10 cm with worst behavior at 0 cm and best behavior at 10 cm. For each behavior the caregiver is instructed to mark their impression of the behavior at baseline visit and again at the six-month visit. The calculated distance in cm between the marks drawn at the baseline and six-month visits thereby demonstrates whether each behavior improved, worsened, or stayed the same during the study, and by how much. Shown here is the mean distance in cm from the worst behavior side for the Language/Communication scale, at the six-month visit. The smaller the value, the worse the behavior. The range is minimum 0 cm to maximum 10 cm.

Time frame: At six-month visit

Population: Placebo group: 5 discontinued treatment, 0 of whom returned to complete follow-up assessments, so 21 subjects were analyzed at follow-up. Sertraline group: 8 discontinued treatment, 2 of whom returned for an end-of-treatment visit, but due to time limitations only 1 of these 2 completed this assessment, so 25 subjects were analyzed at follow-up.

ArmMeasureValue (MEAN)Dispersion
Sertraline Liquid PlaceboVisual Analog Scale - Language/Communication Score5.53 centimetersStandard Deviation 2.95
Sertraline Active MedicationVisual Analog Scale - Language/Communication Score4.70 centimetersStandard Deviation 2.73

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026